Search Results - "Kadia, T"
-
1
New drugs in acute myeloid leukemia
Published in Annals of oncology (01-05-2016)“…The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for the past four decades. Improvements in supportive care and modifications…”
Get full text
Journal Article -
2
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
Published in Leukemia (01-09-2017)“…The PROTAC (proteolysis-targeting chimera) ARV-825 recruits bromodomain and extraterminal (BET) proteins to the E3 ubiquitin ligase cereblon, leading to…”
Get full text
Journal Article -
3
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
Published in Leukemia (01-03-2017)“…Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription…”
Get full text
Journal Article -
4
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse
Published in Leukemia (01-01-2018)Get full text
Journal Article -
5
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
Published in Leukemia (01-02-2016)“…Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). A total of 110…”
Get full text
Journal Article -
6
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
Published in Annals of oncology (01-07-2017)“…T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this study, we report our experience from 119 patients with T-PLL. We reviewed the…”
Get full text
Journal Article -
7
P807: APLASTIC ANEMIA FOLLOWING THE SARS‐COV‐2 VACCINE
Published in HemaSphere (23-06-2022)Get full text
Journal Article -
8
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation
Published in Leukemia (01-04-2013)“…The clinical features and outcomes of 148 patients with acute myeloid leukemia (AML) and 11q23 chromosomal abnormalities were compared with those of 2640…”
Get full text
Journal Article -
9
-
10
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
Published in Leukemia (01-02-2017)“…Most clinical trials exclude patients with poor performance or comorbidities. To study whether patients with these characteristics can be treated within a…”
Get full text
Journal Article -
11
-
12
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
Published in Leukemia (01-07-2017)“…This corrects the article DOI: 10.1038/leu.2016.303…”
Get full text
Journal Article -
13
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL
Published in Bone marrow transplantation (Basingstoke) (01-01-2017)“…Bendamustine has shown a favorable safety profile when included in chemotherapy regimens for several types of lymphoma, including CLL. This study investigated…”
Get full text
Journal Article -
14
P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T‐CELL PROLYMPHOCYTIC LEUKEMIA (T‐PLL)
Published in HemaSphere (23-06-2022)Get full text
Journal Article -
15
P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Published in HemaSphere (23-06-2022)Get full text
Journal Article -
16
P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS
Published in HemaSphere (23-06-2022)Get full text
Journal Article -
17
P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML
Published in HemaSphere (23-06-2022)Get full text
Journal Article -
18
-
19
-
20
P769: MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME
Published in HemaSphere (23-06-2022)Get full text
Journal Article